169 related articles for article (PubMed ID: 29941039)
1. Sustained complete response of advanced hepatocellular carcinoma with metronomic capecitabine: a report of three cases.
Brandi G; Venturi M; De Lorenzo S; Garuti F; Frega G; Palloni A; Garajovà I; Abbati F; Saccoccio G; Golfieri R; Pantaleo MA; Barbera MA
Cancer Commun (Lond); 2018 Jun; 38(1):41. PubMed ID: 29941039
[TBL] [Abstract][Full Text] [Related]
2. The power of kindness: curative treatment with metronomic combination in advanced hepatocellular carcinoma.
Brandi G; Di Federico A; Rizzo A; De Lorenzo S; Vasuri F; Brocchi S; Golfieri R; Morelli MC; Frega G; Palloni A
Anticancer Drugs; 2022 Jan; 33(1):e781-e783. PubMed ID: 34407053
[TBL] [Abstract][Full Text] [Related]
3. The role of metronomic capecitabine for treatment of recurrent hepatocellular carcinoma after liver transplantation.
Ravaioli M; Cucchetti A; Pinna AD; De Pace V; Neri F; Barbera MA; Maroni L; Frega G; Palloni A; De Lorenzo S; Ripoli MC; Pantaleo MA; Cescon M; Del Gaudio M; Brandi G
Sci Rep; 2017 Sep; 7(1):11305. PubMed ID: 28900245
[TBL] [Abstract][Full Text] [Related]
4. Metronomic capecitabine in advanced hepatocellular carcinoma patients: a phase II study.
Brandi G; de Rosa F; Agostini V; di Girolamo S; Andreone P; Bolondi L; Serra C; Sama C; Golfieri R; Gramenzi A; Cucchetti A; Pinna AD; Trevisani F; Biasco G;
Oncologist; 2013; 18(12):1256-7. PubMed ID: 24232581
[TBL] [Abstract][Full Text] [Related]
5. Metronomic capecitabine as second-line treatment for hepatocellular carcinoma after sorafenib discontinuation.
Trevisani F; Brandi G; Garuti F; Barbera MA; Tortora R; Casadei Gardini A; Granito A; Tovoli F; De Lorenzo S; Inghilesi AL; Foschi FG; Bernardi M; Marra F; Sacco R; Di Costanzo GG
J Cancer Res Clin Oncol; 2018 Feb; 144(2):403-414. PubMed ID: 29249005
[TBL] [Abstract][Full Text] [Related]
6. Durable complete response of hepatocellular carcinoma after metronomic capecitabine.
Brandi G; de Rosa F; Bolondi L; Agostini V; Di Girolamo S; Nobili E; Biasco G
Tumori; 2010; 96(6):1028-30. PubMed ID: 21388070
[TBL] [Abstract][Full Text] [Related]
7. Metronomic capecitabine as second-line treatment in hepatocellular carcinoma after sorafenib failure.
Granito A; Marinelli S; Terzi E; Piscaglia F; Renzulli M; Venerandi L; Benevento F; Bolondi L
Dig Liver Dis; 2015 Jun; 47(6):518-22. PubMed ID: 25861840
[TBL] [Abstract][Full Text] [Related]
8. Long-lasting response with metronomic capecitabine in advanced hepatocellular carcinoma.
Ballardini P; Marri I; Margutti G; Aliberti C; Benea G; Manfredini R
Tumori; 2010; 96(5):768-70. PubMed ID: 21302626
[TBL] [Abstract][Full Text] [Related]
9. Metronomic capecitabine versus best supportive care as second-line treatment in hepatocellular carcinoma: a retrospective study.
Casadei Gardini A; Foca F; Scartozzi M; Silvestris N; Tamburini E; Faloppi L; Brunetti O; Rudnas B; Pisconti S; Valgiusti M; Marisi G; Foschi FG; Ercolani G; Tassinari D; Cascinu S; Frassineti GL
Sci Rep; 2017 Feb; 7():42499. PubMed ID: 28211921
[TBL] [Abstract][Full Text] [Related]
10. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience.
Pelizzaro F; Sammarco A; Dadduzio V; Pastorelli D; Giovanis P; Soldà C; Rizzato MD; Lombardi G; Lonardi S; Peserico G; Imondi A; Sartori A; Maddalo G; Farinati F
Dig Liver Dis; 2019 Dec; 51(12):1713-1719. PubMed ID: 31320302
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy of metronomic chemotherapy after cool-tip radiofrequency ablation in the treatment of hepatocellular carcinoma.
Wang-Yuan Z; Jiang-Zheng Z; Lu YD; Hao XB; Hong T; Huang F; Lei JH; He ZH; Huang MZ
Int J Hyperthermia; 2016; 32(2):193-8. PubMed ID: 26586093
[TBL] [Abstract][Full Text] [Related]
12. Phase II Trial of Sorafenib in Combination with Capecitabine in Patients with Hepatocellular Carcinoma: INST 08-20.
Patt Y; Rojas-Hernandez C; Fekrazad HM; Bansal P; Lee FC
Oncologist; 2017 Oct; 22(10):1158-e116. PubMed ID: 28687627
[TBL] [Abstract][Full Text] [Related]
13. Complete response of advanced hepatocellular carcinoma with multiple lung metastases treated with sorafenib: a case report.
Inuzuka T; Nishikawa H; Sekikawa A; Takeda H; Henmi S; Sakamoto A; Saito S; Kita R; Kimura T; Osaki Y; Kudo M
Oncology; 2011; 81 Suppl 1():152-7. PubMed ID: 22212950
[TBL] [Abstract][Full Text] [Related]
14. Systemic therapies in elderly patients with advanced hepatocellular carcinoma: Do not forget metronomic capecitabine.
Wilhelmi M
Eur J Surg Oncol; 2021 Aug; 47(8):2208. PubMed ID: 33906788
[No Abstract] [Full Text] [Related]
15. Case analysis of complete remission of advanced hepatocellular carcinoma achieved with sorafenib.
Liu D; Liu A; Peng J; Hu Y; Feng X
Eur J Med Res; 2015 Feb; 20(1):12. PubMed ID: 25649133
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of combining sorafenib with metronomic tegafur/uracil for advanced hepatocellular carcinoma.
Hsu CH; Shen YC; Lin ZZ; Chen PJ; Shao YY; Ding YH; Hsu C; Cheng AL
J Hepatol; 2010 Jul; 53(1):126-31. PubMed ID: 20416968
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapies in elderly patients with advanced hepatocellular carcinoma: do not forget metronomic capecitabine.
Kapacee ZA; McNamara MG; de Liguori Carino N; Lamarca A; Valle JW; Hubner RA
Eur J Surg Oncol; 2021 Aug; 47(8):2209-2210. PubMed ID: 33965291
[No Abstract] [Full Text] [Related]
18. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan.
Kudo M; Ueshima K
Oncology; 2010 Jul; 78 Suppl 1():154-66. PubMed ID: 20616599
[TBL] [Abstract][Full Text] [Related]
19. Metronomic capecitabine in patients with hepatocellular carcinoma unresponsive to or ineligible for sorafenib treatment: report of two cases.
Marinelli S; Granito A; Piscaglia F; Renzulli M; Stagni A; Bolondi L
Hepat Mon; 2013; 13(9):e11721. PubMed ID: 24282421
[TBL] [Abstract][Full Text] [Related]
20. Effect of immune-modulating metronomic capecitabine as an adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma.
He Q; Luo X; Liu L; Zhao C; Li Z; Jin F
BMC Immunol; 2024 May; 25(1):28. PubMed ID: 38710996
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
